Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

Share Price is delayed by 15 minutes
Get Live Data
440.70    -9.30 (-2.07%)
Bid:
440.60
Ask:
440.90
Spread: 0.30 (0.068%)
Market Cap: £11.09b
RTO Live PriceLast checked at - London Stock Exchange

Intraday Rentokil Initial Share Chart

Q3 Trading Update

5 Nov 2015 07:00

RNS Number : 6149E
Rentokil Initial PLC
05 November 2015
 



  

RENTOKIL INITIAL PLC (RTO)

THIRD QUARTER (Q3) TRADING UPDATE

5 November 2015

 

Results

Q3 2015

Growth

YTD 2015

Growth

£m

AER

AER

CER

AER

AER

CER

Revenue

438.0

(0.4%)

4.1%

1,293.3

-

4.3%

Revenue - ongoing operations1

436.2

0.3%

4.8%

1,287.2

0.7%

5.1%

 

 

Overview (CER)Revenue from ongoing operations increased by 4.8% in the quarter. Q3 organic revenue growth was in line with the second quarter at 1.4% with 3.4% growth from acquisitions. Growth in the Emerging (+11.1%) and Growth (+9.3%) quadrants was strong, with revenue in the Protect and Enhance (-1.4%) and Manage for Value (-4.7%) quadrants down on last year. Revenue from ongoing operations for the nine months ended 30 September 2015 ("year-to-date") increased by 5.1% with organic growth of 1.7% and 3.4% from acquisitions.

Performance continues to be strong in the UK, North America, Asia, Pacific and Latin America driven by continued strong growth in pest control. While conditions remain difficult in France and the Netherlands, year-to-date ongoing revenue in the Europe region is in line with last year.

Cash flowYear-to-date operating and free cash flow are ahead of the prior year and we are confident of delivering free cash flow for the year in excess of £100m.

M&AIn Q3 we acquired five businesses, all in pest control in our Emerging and Growth quadrants. Combined annual revenues of the businesses acquired totalled £17m in the 12 months immediately prior to acquisition. Year-to-date we have acquired 19 businesses with combined annual revenues of £38m. As previously announced our acquisition of The Steritech Group Inc completed on 2nd October and the process of integration is underway and on track.

Commenting on trading in Q3, Andy Ransom, CEO of Rentokil Initial plc, said:"We continue to execute our strategy at pace with the recent acquisition of Steritech providing us with a high quality business with national scale in a key growth market. The performance in the majority of the group continues to be strong although trading in Europe, France in particular, remains challenging. Our guidance for the full year is unchanged."

 

 

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

01276 536585 / 07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978 199

John Sunnucks

Bell Pottinger

0203 772 2549

 

 

 

AER - actual exchange rates; CER - constant 2014 exchange rates

 

1ongoing revenue excludes the financial performance of disposed and closed businesses but includes results from acquisitions

 

This announcement contains statements that are, or may be, forward-looking regarding the group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTKMMGMNDRGKZM
Date   Source Headline
31st Mar 20211:16 pmRNSTotal Voting Rights
31st Mar 202110:33 amRNSAnnual Financial Report
30th Mar 20216:23 pmRNSDirector Declaration
24th Mar 20215:55 pmRNSDirector/PDMR Shareholding
12th Mar 20219:00 amRNSAdditional Listing
4th Mar 20217:05 amRNSDirectorate Change
4th Mar 20217:00 amRNSFinal Results
17th Feb 20215:45 pmRNSDirector Declaration
8th Jan 20217:00 amRNSQ4 2020 Acquisitions and Trading Update
27th Nov 20202:25 pmBUSEarly Repurchase(s)
27th Nov 20202:22 pmBUSEarly Repurchase(s)
24th Nov 20205:25 pmRNSDirector/PDMR Shareholding
20th Nov 20207:00 amRNSResult of Tender Offer for Notes due 2021
12th Nov 20209:02 amRNSTender Offer for Notes due 2021
22nd Oct 20207:00 amRNSQ3 Trading Update
8th Oct 20207:00 amRNSSuccessful EUR600m 8-year bond transaction priced
1st Oct 20209:00 amRNSBlock listing Interim Review
28th Aug 20203:40 pmRNSDirector/PDMR Shareholding
7th Aug 20205:24 pmRNSDirector/PDMR Shareholding
30th Jul 20207:00 amRNSInterim Results
6th Jul 20207:00 amRNSDirectorate Change
21st May 202011:00 amRNSDirector/PDMR Shareholding
13th May 20205:15 pmRNSResult of AGM
7th May 20204:45 pmRNSDirector/PDMR Shareholding
27th Apr 20203:50 pmRNSDisclosure of Rights Attached to Equity Shares
17th Apr 202011:59 amRNSDirector/PDMR Shareholding
16th Apr 20207:00 amRNSQ1 Trading Update
14th Apr 20205:26 pmRNSHolding(s) in Company
9th Apr 20204:35 pmRNSDirector/PDMR Shareholding
2nd Apr 20201:36 pmRNSDirector/PDMR Shareholding
1st Apr 20205:33 pmRNSConfirmation of Non-Executive Director Appointment
1st Apr 20209:24 amRNSBlock listing Interim Review
31st Mar 20202:18 pmRNSTotal Voting Rights
30th Mar 202012:37 pmRNSRedemption of 4.5% debenture stock
30th Mar 202012:24 pmRNSRedemption of 5% debenture stock
27th Mar 202011:00 amRNSHolding(s) in Company
26th Mar 20204:41 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
26th Mar 202011:29 amRNSAnnual Financial Report
25th Mar 20207:00 amRNSTrading Update
19th Mar 202011:30 amRNSDirector Declaration
17th Mar 20201:15 pmRNSAdditional Listing
6th Mar 202012:00 pmRNSHolding(s) in Company
27th Feb 20207:05 amRNSDirectorate Change
27th Feb 20207:00 amRNSFinal Results
21st Feb 20204:00 pmRNSHolding(s) in Company
24th Dec 20191:10 pmRNSHolding(s) in Company
19th Dec 20192:40 pmRNSDirector/PDMR Shareholding
17th Dec 20195:10 pmRNSHolding(s) in Company
26th Nov 20196:03 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.